Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Melphalan and Mannitol in Treating Patients With Central Nervous System Cancer
This study is currently recruiting participants.
Study NCT00253721 Information provided by National Cancer Institute (NCI)
First Received: November 11, 2005 Last Updated: August 25, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chordoma
Lymphoma
Metastatic Cancer
Von Hippel-Lindau Syndrome
Additional conditions recognized in this trial
Astrocytoma
Central Nervous System Neoplasms
Neoplasm Metastasis
Nervous System Neoplasms
Syndrome
Von Hippel-Lindau Disease
More general conditions related to this trial
Angiomatosis
Cardiovascular Diseases
Disease
Glioma
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neoplastic Processes
Nervous System Diseases
Neurocutaneous Syndromes
Neuroectodermal Tumors
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
mannitol
melphalan
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Cardiovascular Agents
Diuretics
Diuretics, Osmotic
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Oregon Health and Science University
National Cancer Institute (NCI)
Back to top of Main Content
